Domain Bridging Interactions in the Allosteric Network for IIAGlc Inhibition of the Escherichia coli Glycerol Kinase by Acquaye, Edith Abena
 
 
 
 
 
DOMAIN BRIDGING INTERACTIONS IN THE ALLOSTERIC NETWORK 
FOR IIA
GLC
 INHIBITION OF THE ESCHERICHIA COLI GLYCEROL KINASE  
 
 
A Thesis 
by 
EDITH ABENA ACQUAYE  
 
 
Submitted to the Office of Graduate Studies of 
Texas A&M University 
in partial fulfillment of the requirements for the degree of  
MASTER OF SCIENCE 
 
 
August 2010 
 
 
Major Subject: Biochemistry
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Domain Bridging Interactions in the Allosteric Network for IIAGlc Inhibition of the 
Escherichia coli Glycerol Kinase  
Copyright 2010 Edith Abena Acquaye 
 
  
 
 
 
DOMAIN BRIDGING INTERACTIONS IN THE ALLOSTERIC NETWORK 
FOR IIA
GLC
 INHIBITION OF THE ESCHERICHIA COLI GLYCEROL KINASE  
 
A Thesis 
by 
EDITH ABENA ACQUAYE   
 
Submitted to the Office of Graduate Studies of 
Texas A&M University 
in partial fulfillment of the requirements for the degree of  
MASTER OF SCIENCE 
 
Approved by: 
Chair of Committee,  Donald W. Pettigrew 
Committee Members, Mary Bryk 
 Frank Raushel  
Head of Department, Gregory Reinhart 
 
August 2010 
 
Major Subject: Biochemistry
 iii 
ABSTRACT 
 
Domain Bridging Interactions in the Allosteric Network for IIAGlc Inhibition of the 
Escherichia coli Glycerol Kinase. (August 2010) 
Edith Abena Acquaye, B.Sc., University of Ghana 
Chair of Advisory Committee: Dr. Donald W. Pettigrew 
  
Previous studies on inhibition of the Escherichia coli glycerol kinase enzyme 
have suggested that subunit-subunit or domain bridging interactions form part of the 
network in communicating ligand binding to inhibition. In this study, five amino acids 
were identified to be in close proximity to an Arg369 residue which is a domain bridging 
residue. Three of the amino acid residues (Q37, Y39 and Q104) are in domain I of the 
enzyme subunit, while the other two (M308 and Q314) are in domain II of the enzyme 
subunit. 
To evaluate the importance of each domain bridging residue in IIAGlc inhibition, 
alanine substitutions were made of the residues, and the kinetic properties characterized 
with respect to IIAGlc inhibition. Kinetic parameters obtained for each variant glycerol 
kinase enzyme was compared to values obtained for the Wild Type enzyme to assess the 
importance of the amino acid residue in IIAGlc inhibition. The effects of the substitutions 
on FBP inhibition as well as catalysis of the enzyme were also analyzed by obtaining 
kinetic parameters for each of the variant enzymes.  
 iv
The results from this study indicate that the domain I bridging interactions with 
Arg369 are important in IIAGlc regulation of the E. coli glycerol kinase enzyme. The 
domain II bridging interactions appear to be unimportant in regulating IIAGlc inhibition. 
Two of the domain I bridging residues studied were also found to be important in FBP 
inhibition. These results indicate that some the domain bridging residues seen to be 
involved in IIAGlc regulation also appear to be involved in FBP regulation. In catalysis, 
with the exception of Q314, the rest of the domain I and II bridging residues appear to be 
important for substrate binding and/or catalysis.  
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CHAPTER I 
INTRODUCTION 
 
Under low glucose conditions, glycerol can be metabolized to provide energy in 
E. coli. Studies of glycerol metabolism have revealed two modes of glycerol 
dissimilation in bacteria. In the first mode, glycerol may be oxidized to 
dihydroxyacetone (DHA), and then phosphorylated to dihydroxyacetone phosphate 
(DHAP), while in the second method, glycerol is phosphorylated to glycerol-3-
phosphate (G3P), and then oxidized to DHAP. Both routes however result in the 
terminal product DHAP which enters the glycolytic pathway to provide energy for the 
organism (1). The enzymes involved in the preliminary steps of glycerol dissimilation 
are outlined below.  
Mode A: 
Enzyme 1: Glycerol dehydrogenase (EC l . l . l .6; Glycerol:NAD+ 2-oxidoreductase): 
Reaction 1: Glycerol + NAD+ ↔ DHA + NADH + H+ 
Enzyme 2: DHA kinase (EC 2 . 7 . 1 .28: Triokinase) 
Reaction 2: DHA + ATP → DHAP + ADP 
_________ 
This thesis follows the style of the Journal of Biological Chemistry. 
1.    The abbreviations used are: IIAGlc, enzyme of the PTS which is specific for glucose; 
βME, 2-mercaptoethanol; DHA, dihydroxyacetone; DHAP, dihydroxyacetone 
phosphate; FBP, fructose-1,6-bisphosphate; G3P, glycerol-3-phosphate; glp, glycerol 
phosphate regulon; IPTG, isopropylthiogalactoside; nH, Hill Coefficient; MGSA, 
MacConkey glycerol plates containing streptomycin and ampicillin; PTS, 
phosphoenolpyruvate:glycose phosphotransferase system; SDS, sodium dodecyl sulfate; 
TEA, triethanolamide; single and three letter abbreviations are used for amino acids. 
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Mode B:  
Enzyme 1: Glycerol kinase (EC 2 .7. 1 .30; ATP:glycerol 3-phosphotransferase): 
Reaction 1: Glycerol + ATP → G3P + ADP 
Enzyme 2: Glycerol-3-phosphate dehydrogenase (EC 1 . 1 . 1 .8; sn-Glycerol-3-
phosphate:NAD+ 2-oxidoreductase) 
Reaction 2: G3P → DHAP 
The phosphorylation of glycerol to glycerol-3-phosphate by the enzyme glycerol kinase 
has been found to be a key regulatory step in glycerol metabolism (1, 2). The EcGK is 
encoded by the glpK gene whose transcription is upregulated with other genes needed 
for glycerol metabolism (3, 4). The crystal structure of EcGK shows that it is a member 
of the sugar kinase kinase/actin/heat shock protein 70 (hsp 70) superfamily of proteins 
(5). These proteins are characterized by two large domains, I and II, one on either side of 
a deep narrow ATPase catalytic cleft (6, 7, 8). As with other sugar kinases, ligand 
binding to the EcGK is presumed to affect closure of the catalytic site cleft due to 
movement of one domain relative to the other (9, 10, 11). The catalytic activity of EcGK 
has been found to be activated by ATP which displays apparent two classes of binding 
sites, glycerol, (12) and by interaction with the glycerol facilitator (13). The Michaelis 
constants have been found to be 10-fold less than the substrate dissociation constants, 
suggesting that some step after the formation of the ternary complexes may be at least 
partially rate limiting (12).  
When glycerol is not needed as a carbon source, the activity of EcGK is 
allosterically regulated by the glycolytic intermediate fructose-1,6-bisphosphate (FBP) 
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(14), and the glucose-specific phosphocarrier protein of the 
phosphoenolpyruvate:glycose phosphostransferase system, IIAGlc (15). Regulation of 
EcGK by FBP is by feedback inhibition and has been found to display characteristics of 
a V system (14). EcGK exists in a dimer-tetramer equilibrium with the dimer being the 
active form and the tetramer being the inactive form. FBP binding has been shown to 
shift the equilibrium strongly towards the tetramer therefore effecting inhibition (16). In 
contrast, regulation by IIAGlc has been found to be via protein-protein interactions (5, 17, 
18). IIAGlc may be phosphorylated on the active site His90 which is the prevalent form of 
IIAGlc when extracellular glucose is not available (18). Unphosphorylated IIAGlc is thus 
the form which inhibits EcGK when glucose is available. The two allosteric inhibitors, 
FBP and IIAGlc, bind at distances of 35 Å and 30 Å, respectively, from the enzyme 
catalytic site (5). FBP binds only in domain I while IIAGlc binds only in domain II, 
raising the question of how the perturbations due to ligand binding at separate regions of 
the enzyme are propagated to the distant catalytic site in this oligomeric protein to result 
in inhibition. It is thought that the regulation of EcGK by the two allosteric inhibitors 
IIAGlc and FBP are independent of each other and can be genetically separated (18, 19).  
Analysis of the x-ray crystallographic structure of the E. coli glycerol kinase 
(EcGK) has not offered a complete insight into the allosteric inhibition of the enzyme. 
The structural basis for the allosteric control of EcGK appears different from that of the 
other members of the superfamily that EcGK belongs to (20). For most of the other 
superfamily members, including hexokinases, actin, and hsp 70, their crystal structures 
show that their allosteric effectors interact with both domains and it is generally believed 
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that the effectors act directly on the cleft closure (20). For these superfamily members, it 
appears that their allosteric regulation is as a result of direct steric action on the cleft 
closure due the interactions of the allosteric effectors with both domains. In EcGK 
however, the mechanism of allosteric regulation by IIAGlc and FBP does not appear to be 
due to direct steric action on the catalytic site closure because each allosteric effector is 
found to bind in only one domain.  
Current views on allosteric control of proteins have expanded on the classical 
view of allostery (21, 22). In the classical view, regulation of protein function by 
allosteric effectors was thought to be due to conformational changes that reflect global 
cooperativity within the protein (23, 24).  Recent studies of the allosteric control of 
proteins however indicate that allosteric behavior may occur as a result of changes in 
local interactions among a few amino acid residues (25, 26, 27, 28). These amino acids 
are thought to form networks for long-range energetic interactions in proteins (25). 
Previous studies of EcGK suggest that subunit-subunit/domain interactions of the E. coli 
glycerol kinase enzyme may be important for ligand binding of its allosteric inhibitors 
and subsequent inhibition. Such interactions may form part of the network for the 
allosteric control of EcGK; this would be in agreement with the current views of 
allosteric control of proteins.  
In 1993, Hurley et al. (5) suggested that the amino residue, Arg369, may be 
involved in the allosteric regulation of glycerol kinase. They reached this conclusion 
from analysis of the crystal structure of the glycerol kinase enzyme with the substrates 
ADP and glycerol, which showed Arg369 as present on a loop from one subunit which 
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penetrates deeply, approaching approximately 7 Å of the ADP molecule in the next 
subunit. Recent studies by Pettigrew (20) agreed with the hypothesis of Hurley et al. (5) 
by showing that truncation of the Arg369 residue with an R369A mutation resulted in a 
reduction of the inhibition of glycerol kinase by one of its allosteric inhibitors IIAGlc. 
The results also showed that inhibition by the other allosteric inhibitor FBP was not 
affected by the R369A substitution. Liu et al. in 1994 (29) also showed that an A65T 
mutation in glycerol kinase resulted in abolishing inhibition of glycerol kinase by FBP. 
Analysis of the crystal structure of the enzyme showed that this mutation is associated 
with an α-helix that constitutes one of the two subunit-subunit interfaces within the 
tetramer. These observations support the premise that the domain interactions of the 
Arg369 residue of the E. coli glycerol kinase enzyme may be important in the network of 
amino acid residues which communicate changes due to IIAGlc binding in the allosteric 
regulation of the enzyme.  
The crystal structure of EcGK shows that the Arg369 side chain from one subunit 
interacts with both domains of the other subunit. A close inspection of the domain 
bridging interactions shows three amino acids in domain I (Q37, Y39, Q104) with side 
chains within 3.5Å of the guanidino group of Arg369 and two amino acids in domain II 
(M308, Q314) with side chains within 4.8 Å of the guanidino group of Arg369. In this 
study, amino acid substitutions were therefore made for the five amino acid residues 
identified within 7 Å of the residue Arg369 to assess the contribution of the hydrogen 
bonding interactions between the side chains of the amino acids residues and the 
guanidino group of the Arg369 in the regulation of the enzyme by IIAGlc. The inhibition 
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parameters obtained were then compared to the Wild Type enzyme. Kinetic parameters 
were also obtained from measuring the extent of inhibition of the variant enzymes by 
FBP. The contribution of each domain interaction with Arg369 in the catalytic activity of 
the enzyme was determined from comparing the catalytic kinetic parameters obtained for 
the Wild Type and variant glycerol kinase enzymes.  
Some of the recent studies on the contributions of individual amino acids in 
enzyme catalysis and regulation use NMR spectroscopy as a useful tool because it is 
sensitive to molecular motion over a wide variety of timescales. The subunit size of the 
tetrameric EcGK is approximately 56 kD, which exceeds the protein NMR size limit of 
35 kD (30), therefore preventing the use of NMR to investigate the role of specific 
amino acid residues in EcGK. Structure perturbation studies have however proved to be 
a powerful alternative approach in studies of protein regulation. The effects of changes 
in the regulatory properties of the protein due to specific changes in the primary 
structure of the protein can be analyzed.  
In this study, structure perturbation was used to study the five amino acids 
identified in close proximity to Arg369. Amino acid substitutions were made and the 
effects of the mutations assessed by using kinetics to characterize the regulatory 
properties. The following specific aims were used to address the objective of 
understanding the role and contribution of the domain bridging interactions in the 
regulation of EcGK by IIAGlc.  
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Specific Aims 
1. Construction and purification of glycerol kinase variants with amino acid 
substitutions of the residues flanking the Arg369 residue. 
2. Characterization of the IIAGlc regulatory properties as well as the catalytic 
properties and regulation by FBP of the variant glycerol kinase enzymes. 
3. Evaluation of the contribution of each domain interaction with Arg369. 
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CHAPTER II 
MATERIALS AND METHODS 
 
Materials 
Chemicals and enzymes were purchased from Sigma-Aldrich Chemical Co. (St. 
Louis, Mo.) unless otherwise stated. The enzyme IIAGlc used in this study was purified 
from pVEX-crr plasmids expressing the IIAGlc encoding sequence and purified from the 
BL21 (DE3) strain of E. coli bearing the plasmid as described (31). The pVEX-crr 
plasmid was generously provided by Dr. Saul Roseman, Department of Biology, Johns 
Hopkins University (Baltimore, MD). SDS electrophoresis reagents were purchased 
from Fisher. Plasmid purification kits were purchased from Qiagen Sciences (Valencia, 
CA). The QuikChange™ site directed mutagenesis method was used for the purposes of 
this study 
 
Strains and Plasmids 
The strain of E. coli used in this study was the K12 DG1 (genotype: F- ara 
glpR208 ∆(lac-proAB) rpL (Strr) [Φ80dlac∆(lacZ)M15] thi glpK202) strain, which is 
streptomycin resistant and ampicillin sensitive. This strain of E. coli was constructed in 
the Pettigrew laboratory to provide a glycerol kinase deletion background for 
mutagenesis work. The pWT165 plasmid vector contains the Wild Type glycerol kinase 
gene and confers ampicillin resistance for positive selection of transformed cells. The 
pWT165 plasmid was previously constructed by cloning the Hind III fragment that 
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contains the glycerol kinase gene from the rfMl3 DNA that was used in the sequencing 
of the gene (32) into the vector pHG165 (33). Single mutations were introduced in the 
glycerol kinase encoding sequences by using the QuikChange™ site directed 
mutagenesis method for the purposes of this study. 
 
Mutant Plasmid DNA Construction 
Single mutations were introduced in the glycerol kinase encoding sequences by 
using the QuikChange™ site directed mutagenesis method. Table 1 shows the sites of 
the single amino acid substitutions that were made in the glycerol kinase coding 
sequence. Amino acid residues in domain I and II which are in close proximity to the 
Arg369 residue were substituted with alanine. One amino acid residue in domain I, Y39, 
was also substituted with phenylalanine to assess the contribution of the hydroxyl group 
interaction of the tyrosine residue with Arg369.  
 
 
 
 
 
 
 
 
 
 10
Table 1: Sites of single amino acid substitutions introduced into the glycerol kinase 
sequence  
Domain I substitutions    Domain II substitutions 
 
Q37A        M308A  
Y39A        Q314A 
Q104A 
Y39F 
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The native sequences below contain the sites for introducing the single mutations 
into the glycerol kinase encoding sequence. The desired sites for substitutions are 
underlined. The variant sequences with the desired mutations were used as primers for 
the site directed mutagenesis. For the alanine substitutions, the mutation site codon was 
changed to GCG (a codon for alanine) in primer 1 and CGC (anticodon) in primer 2. For 
the Y39F substitution however, the mutation site codon was changed to TTT (a codon 
for phenylalanine) in primer 1 and AAA (anticodon) in primer 2.  
 
Q37A  
PRIMER 1: 5’ - CAG CGC GAA TTT GAG CAA ATC TAC CCA AAA CCA - 3’ 
PRIMER 2: 5’ - TGG  TTT TGG  GTA GAT TTG CTC AAA TTC GCG CTG - 3’ 
 
Y39A 
PRIMER 1: 5’- GAA TTT GAG CAA ATC TAC CCA AAA CCA GGT TGG - 3’ 
PRIMER 2: 5’-  CCA ACC TGG TTT TGG  GTA GAT  TTG CTC AAA TTC - 3’ 
 
Y39F 
PRIMER 1: 5’ - GAA TTT GAG CAA ATC TTT CCA AAA CCA GGT TGG - 3’ 
PRIMER 2: 5’-  CCA ACC TGG TTT  TGG AAA GAT TTG  CTC AAA TTC - 3’ 
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Q104A 
PRIMER 1: 5’ - AAC GCC ATT  GTC TGG CAG TGC CGT CGT ACC GCA - 3’ 
PRIMER 2: 5’- TGC GGT ACG ACG GCA CTG CCA GAC AAT GGC GTT - 3’ 
 
M308A  
PRIMER 1: 5’ - GAA GGT GCG GTG TTT ATG GCA GGC GCA TCC ATT - 3’ 
PRIMER 2: 5’-  AAT GGA TGC GCC TGC CAT AAA CAC CGC ACC TTC - 3’ 
 
Q314A  
PRIMER 1: 5’- GCA GGC GCA TCC ATT CAG TGG CTG CGC GAT GAA - 3’ 
PRIMER 2: 5’ - TTC ATC GCG CAG CCA CTG AAT GGA TGC GCC TGC - 3’ 
The mutant strands were generated by PCR thermocycling using the conditions outlined 
below: 
1. 94oC for 1 minute  
2. 94oC for 30 seconds 
3. 59.8oC for 30 seconds 
4. 68oC for 20 minutes 
Repeat steps 2 to 4 for 15 cycles  
5. 68oC for 10 minutes 
6. 4oC - Hold 
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Transformation of E. coli and Verification of Mutant Plasmids 
The transformation of E. coli with the appropriate mutant plasmid was done by the 
calcium chloride method (34). Cells successfully transformed with the mutant plasmids 
were screened on MacConkey-glycerol plates containing ampicillin and streptomycin 
sulfate (MGSA plates). Cells containing the glpK gene in pWT165 plasmid are pink to 
purple on MacConkey glycerol agar depending on their ability to metabolize glycerol. 
The antibiotics ampicillin and streptomycin sulfate where indicated were added to final 
concentrations of 75µg/ml and 200µg/ml respectively. Transformants were then streaked 
on MGSA and single colonies picked and grown in 1X LB broth containing ampicillin 
and streptomycin sulfate (LBSA). Plasmid DNA was then purified from the cell cultures 
using the Qiagen™ miniprep DNA purification kit.  The purified plasmid DNA was 
sequenced and verified for incorporation of the desired amino acid substitution in the 
glycerol kinase gene. The primers used for sequencing the glycerol kinase sequence are 
written out in Table 2. The plasmid DNA from each glycerol kinase variant was 
sequenced using the ABI Big Dye method. The reactions were performed by using a 
reaction mix containing 400-600ng of speed vacuum dried purified DNA, 1µl of a 10µM 
stock of each primer, 2µl of ABI Big Dye (a polymerase, dideoxynucleotides mix),and 
3µl sterile milliQ water. The thermocycling conditions for the sequencing reaction were 
as follows: 
1. 95oC for 2 minutes 
2. 95 oC for 30 seconds 
3. 50 oC 15 seconds 
 14
4. 60 oC 4 minutes 
Repeat steps 2 to 4 for 99 cylces 
5. 4 oC - Hold 
The PCR products were cleaned by gel filtration using spin columns provided by 
the Gene Technologies Laboratory, Department of Biology, TAMU. The cleaned 
products of the sequencing reactions DNA were air dried in a SpeedVac and analyzed by 
the Gene Technologies Laboratory, Department of Biology, TAMU. The sequences 
obtained were then verified for correct incorporation of the desired single mutation by 
comparing each sequence to the Wild Type glycerol kinase sequence using the 
Sequencher® 4.1.4 software. 
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Table 2: Primer sequences used for amplification and sequencing of the glycerol kinase 
gene 
PRIMER NAME  SEQUENCE     GC CONTENT Tm 
 
DP 1   TGGCGAAAGCCGATATCAGTT        47.6                 56.8   
DP 2    GTGGAAGGCTCTCGCGAGCGT      66.7   64.3 
DP 3    GGCAAAGGCGGCACGCGTATT      61.9   63.7 
DP 4   TGGCTGCGCGATGAAATGAAG       52.4  58.7 
DP 5   GGCCGACTCTGGTATCCGTCT      61.9  60.7 
DP 6   TACCGTTACGCAGGCTGGAAA      52.4   58.8 
 
P 1   GACACGCTAATGATATTGGCA         42.9  53.0 
P 2   AATGCTCGCAGATTTCTGCGG          52.4  58.5 
P 3   AACAGCAATTCACCACGACGT         47.6  57.5 
P 4   CAGTGCCATAGGTGTTCTTCG           52.4  55.8 
P 5   CGGAATCGTAGGCGTCGTTAA          52.4  57.0 
P 6   TCGGACTGGAACTGCATCAGG          57.1  59.2 
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Enzyme Purification 
The variant glycerol kinase enzymes (Q37A, Y39A, Y39F, Q104A, M308A, and 
Q314A) were expressed and purified as described by Pettigrew et al., (35) with the 
following modifications: The enzyme was expressed from the pWT165 plasmid and not 
the pCJ102 plasmid. The transformed cells were grown in cultures containing both 
ampicillin and streptomycin. The purification procedure involved usage of a GE 
Pharmacia ATKA™ purifier system.   
Overexpression of Enzyme 
The E. coli cells containing the variant glycerol kinases were grown in 1 L of 2X 
LB broth containing streptomycin and ampicillin. Each culture was grown in a 37oC 
shaker overnight. The next day, the overnight culture was induced for three hours with 
IPTG at a concentration of 1 mM. The resulting cell cultures were spun at 6,000 rpm at 
4oC for 10 minutes, in a Sorvall RC5-B refrigerated super-speed centrifuge using a GS3 
rotor. The harvested cells were stored at -20oC until used. 
Cell Lysis 
Before cell lysis, the cells were resuspended in four volumes of glpK standard 
buffer pH 8.0 composed of 50 mM TEA, 2 mM glycerol, 1 mM EDTA and 2 mM βME 
(12). A W-220F sonicator with a microtip (Heat systems – Ultrasonics, Inc) was used to 
lyse the cells. The cells were sonicated for 10 minutes using 2 seconds sonication/3 
seconds off cycling, in a salt ice-bath, with the temperature of the cell suspension 
maintained below 10oC.  The resulting cell suspension was centrifuged at 12,000 rpm in 
a FiberLite F15S-8X50C rotor and the supernatant tested for activity.  
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Enzyme Purification 
The supernatant from the cell lysis was taken through steps of addition of 
streptomycin sulfate and ammonium sulfate to precipitate out nucleic acids and finally 
the glycerol kinase proteins. The streptomycin and ammonium sulfate steps were carried 
out in the cold unless indicated otherwise. The enzymes were purified using the AKTA 
purifier system which combines Q-Sepharose HP and Source 15Q affinity 
chromatography systems.  Each enzyme was stored as a crystalline ammonium sulfate 
suspension as described (35). 
Streptomycin Sulfate Treatment 
To precipitate nucleic acids, 20% streptomycin sulfate in glpK standard buffer 
pH 8.0 was added slowly to the crude supernatant while stirring continuously.  The 
volume of the 20% streptomycin sulfate prepared and added was 1/10th the volume of 
the crude supernatant. The mixture was stirred for an additional 30 minutes and then 
centrifuged for 10 minutes in the FiberLite F15S-8X50C rotor at 12,000 rpm. The 
supernatant volume was measured, labeled SSR and an aliquot assayed for activity. The 
pellet was stored at 4oC. 
Ammonium Sulfate Treatment 
The streptomycin sulfate treated supernatant was taken through two ammonium 
sulfate treatments to first precipitate out unwanted proteins and then to precipitate out 
the EcGK. In the first ammonium sulfate treatment, finely ground ammonium sulfate 
(24g/100 mL SSR) was slowly added with constant stirring. The stirring was continued 
for an additional 30 minutes in the cold room after which the solution was centrifuged 
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for 10 minutes in the FiberLite F15S-8X50C rotor at 12,000 rpm. The supernatant 
volume was measured, labeled ASSI and an aliquot assayed for activity. The resulting 
pellet was stored at 4oC. The ASSI was then taken through the second ammonium sulfate 
treatment by adding 22g/ 100 mL ASSI of finely ground ammonium sulfate while 
stirring continuously. The stirring was continued for an additional 30 minutes and the 
mixture centrifuged for 10 minutes in the FiberLite F15S-8X50C rotor at 12,000 rpm. 
The supernatant was labeled ASSIIsupe and the volume measured. The ASSIIsupe was 
assayed to make sure no activity was left in the ammonium sulfate fraction. The pellet 
was then resuspended in standard buffer pH 8.0 (1/10th the volume of the ASSIIsupe), 
and dialyzed overnight versus 1 L of standard buffer pH 8.0 and labeled ASSIIpptd. The 
ASSIIpptd was assayed for activity the next day. 
Column Purification 
 The proteins were then purified using the AKTATM purifier system which 
combined Q-Sepharose HP and Source 15Q affinity chromatography systems. The 
ASSIIpptd was first centrifuged at 12,000 rpm for 10 minutes in the FiberLite F15S-
8X50C rotor and then syringe filtered with the Millipore filter (0.45 µM). The protein 
was then run on the Q-Sepharose HP column (approximately 2.6 cm x 11.8 cm) with 
standard buffer pH 8.0 and eluted with 10-50% NaCl in standard buffer pH 8.0. Enzyme 
containing fractions as determined by assaying for enzyme activity were pooled. The Q-
Sepharose HP pool was then dialyzed against 1 L of standard buffer pH 7.0 and assayed 
for activity. The Q-Sepharose HP pool was centrifuged at 12,000 rpm for 10 minutes in 
the FiberLite F15S-8X50C rotor; syringe filtered and then run through the first Source 
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15Q column at pH 7.0 (approximately 1.5 cm x 11.2 cm); the column was then eluted 
with a 10-50% NaCl in standard buffer pH 8.0.  Enzyme containing fractions were 
pooled and dialyzed against 1 L of standard buffer pH 8.0. The Source 15Q pH 7.0 pool 
was then centrifuged at 12,000 rpm for 10 minutes in the FiberLite F15S-8X50C rotor; 
syringe filtered and then run through the second Source 15Q column at pH 8.0 and 
eluted with 10-50% NaCl gradient. The protein concentrations and enzyme activity of 
enzyme containing fractions were determined from the absorbance at 280nm on a 
Beckman UV/Vis DU800 spectrophotometer using an extinction coefficient of 1.73 
(mg/mL)-1cm-1 (36), and by assaying for enzyme activity respectively. Homogeneity of 
the purified glycerol kinase enzyme was then determined using SDS-PAGE with 
GelCode Blue stain, and pure fractions pooled. The purified proteins were dialyzed 
against standard buffer pH 8.0 and concentrated by ultrafiltration using the 30 000 kD 
molecular weight cut-off Centricon® centrifugal filter device. Each enzyme was stored 
as a crystalline ammonium sulfate suspension as described (35). 
Preparation of Purified Enzyme for Initial Velocity Studies and Inhibition Assays  
Before each experiment, each enzyme was passed through a NAP-10 mini-
column. The mini-column was first washed with three column volumes of standard 
buffer, pH 7.0 to equilibrate the column. A volume of the enzyme diluted in standard 
buffer, pH 7.0 and made up to 1 mL was loaded onto the equilibrated mini-column and 
the flow-through discarded. A volume of 1.4 mL of standard buffer, pH 7.0 was then 
loaded unto the mini-column and the flow-through collected for protein concentration 
and subsequent enzyme activity analysis. This served to remove the ammonium sulfate 
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that the enzymes were stored in. The concentration of the enzyme after passing through 
the mini-column was determined from the absorbance at 280nm on a Beckman UV/Vis 
DU800 spectrophotometer using an extinction coefficient of 1.73 (mg/mL)-1cm-1 (36).  
 
Enzyme Assays 
IIA
Glc
 Inhibition Studies 
IIAGlc inhibition of the enzyme activity of the glycerol kinase variants was 
measured in the forward reaction (glycerol to glycerol-3-phosphate) using the 
continuous ADP-coupled spectrophotometric assay at pH 7.0 and 25°C with a Beckman 
DU800 spectrophotometer.  The enzyme inhibition assay is composed of a 0.5 mL 
solution of 50mM triethanolamine-HCl buffer, 5 mM MgCl2, 20 mM KCl, 7.5 units each 
of pyruvate kinase and lactate dehydrogenase, 0.2 mM PEP, 0.2 mM NADH, 10 mM 
glycerol and 2.5 mM ATP with varying concentrations of IIAGlc from 0- 60 µM. The 
assay was initiated by the addition of the enzyme. Data were fit to equation 1 below 
using the Kaleidagraph software (Synergy Software, Reading, PA). The glycerol kinase 
enzyme concentration in each assay was varied from 0.5 to 5 µg/ml, depending on the 
activity of the variant enzyme. For each of the variant enzymes, the inhibition parameter 
K0.5 which is the apparent dissociation constant for allosteric effector binding was 
determined from the fits of the data to equation 1. 
 
]X[K
]X)[SASA(
SASA
5.0
o
o]X[ +
−
−= ∞      (1) 
 
- X is the allosteric inhibitor IIAGlc,  
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- SA[X] is the specific activity at the concentration of the inhibitor,  
- SA0 is the specific activity in the absence of the inhibitor,  
- SA∞ is the specific activity in the saturating presence of inhibitor,  
- K0.5 is equal to the concentration of X that gives 50% of the maximum 
inhibition. 
Another inhibition parameter, W, is the coupling parameter which describes the effect of 
the allosteric ligand on Vmax and was determined from equation 2 below.  
  
oSA
SA
W ∞=      (2) 
where SA∞ – SA at saturating levels of the inhibitor 
 SAo – SA in the absence of the inhibitor  
The value of W is >1 if the allosteric effector increases the Vmax, and is <1 if Vmax is 
reduced by the allosteric effector. Where there is no allosteric effect on Vmax, W equals 
1.  
FBP Inhibition Studies 
The FBP inhibition assay also had the same components of the IIAGlc inhibition 
assay except FBP concentrations were varied from 0- 10 mM. Also, the reaction assay 
was incubated with the enzyme and FBP for 90 minutes before initiating the reaction by 
the addition of ATP. Data were fit to the equation 3 below using the Kaleidagraph 
software (Synergy Software, Reading, PA). 
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- X is the allosteric inhibitor FBP,  
- SA[X] is the specific activity at the concentration of the inhibitor,  
- SA0 is the specific activity in the absence of the inhibitor,  
- SA∞ is the specific activity in the saturating presence of inhibitor,  
- K0.5 is equal to the concentration of X that gives 50% of the maximum 
inhibition, 
- nH is the Hill Coefficient and describes the binding cooperativity of the 
allosteric effector.  
The glycerol kinase enzyme concentration in the FBP assays was varied from 0.5 to 5 
µg/ml, depending on the activity of the variant enzyme. For each of the variant enzymes, 
the inhibition parameter K0.5 which is the apparent dissociation constant for allosteric 
effector binding was determined from the fits of the data to equation 3. The coupling 
parameter W, for FBP inhibition was determined from equation 2.  
Enzyme Catalytic Activity Assays 
The assays to assess the catalytic activity of the variant enzymes had the same 
components of the inhibition assays except the substrate ATP was varied from 0 - 2.5 
mM and no inhibitor was added to the assays. Wild Type EcGK has been shown to 
display two classes of ATP binding sites (12). The determination of kinetic parameters is 
more accurate for the first ATP binding site. ATP concentrations were therefore varied 
from 0 – 0.1 mM to obtain the kinetic parameters for assessing the catalytic properties. 
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For variants where the substitutions appeared to decrease the ATP binding affinity , the 
ATP concentrations were varied up to 2.5 mM. Kinetic data was fit to the Michaelis-
Menten equation 4 below using the Kaleidagraph software (Synergy Software, Reading, 
PA).  
 
ATP
m
max
o
K]ATP[
]ATP[V
v
+
=      (4) 
 
where the catalytic activity of the enzymes with respect to the substrate glycerol was 
assessed, glycerol concentration was varied from 0 – 1.6 mM, while ATP was varied 
from 0 – 2.5 mM. Kinetic data was fit to equation 5 below for a bi-substrate enzyme 
kinetics mechanism using the program EnzFitter (Biosoft, Cambridge, U.K.). The 
concentration of glycerol kinase enzyme used in the enzyme assays varied from 0.5 to 5 
µg/ml, depending on the activity of the variant enzyme. 
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- vo is the intial velocity at the concentration of substrate,  
- Vmax is the maximum velocity at saturating conditions of the substrate,  
- [ATP] is the concentration of ATP,  
- Km
ATP is the Michaelis constant for ATP,  
- [gol] is the concentration of glycerol, 
- Kia
ATP
 is the dissociation constant for ATP,  
- Km
gol is the Michaelis constant for glycerol. 
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IIA
Glc
 Binding Studies 
Sedimentation velocity experiments were used to assess IIAGlc binding to EcGK 
as described (37). Purified glycerol kinase protein samples were diluted to 0.3 mg/mL of 
glycerol kinase with standard buffer, pH 7.0. The IIAGlc concentration was varied from 0 
up to 90 µM. Samples were run in a Beckman model XL-A analytical ultracentrifuge at 
28,500 rpm and 25°C. Scans were performed at 280 nm with 4 minute intervals between 
scans. The data obtained were analyzed using the SVEDBERG program (version 6.38) 
to obtain the apparent sedimentation coefficient. The dissociation constant for IIAGlc 
binding to glycerol kinase was determined by fitting the IIAGlc concentration dependence 
of the apparent sedimentation coefficients (Sapp) to equation 6. 
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- So is the sedimentation coefficient in the absence of IIA
Glc,  
- S∞ is the sedimentation coefficient in the saturating presence of IIA
Glc,  
- Sapp is the apparent sedimentation coefficient, 
- [GK]TOT is the concentration of total enzyme, 
- [IIAGlc]TOT is the concentration of total IIA
Glc, 
- Kd is the dissociation constant. 
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CHAPTER III 
RESULTS 
 
Construction and Purification of Variant Glycerol Kinases 
E. coli cells transformed with the products of the mutagenized DNA were 
selected on MGSA plates. Five to ten pink to purple colonies indicative of glycerol 
utilization were selected for sequencing to identify the mutants. Plasmid DNA purified 
from the E. coli cells which were sequenced confirmed at least one selected colony with 
the desired single mutations introduced into the glycerol kinase gene with no secondary 
mutations. 
The variant glycerol kinase enzymes Q37A, Y39A, Y39F, Q104A, M308A and 
Q314A were purified as outlined in the materials and methods section. During the 
purification steps, ammonium sulfate solubility of the variant enzymes was comparable 
to that of the Wild Type and to each other. Elution positions on the Q-Sepharose and 
Source 15Q chromatography columns were similar, suggesting that the structure of the 
enzyme was not grossly altered by the mutations incorporated. Each enzyme was 
purified as shown in the SDS-PAGE gel image (Figure 1). However, the specific activity 
after the final purification step of each variant enzyme varied. Wild Type glycerol kinase 
was found to have a specific activity of approximately 39 U/mg. Q37A, Y39F, Q104A 
and Q314A had specific activities comparable to Wild Type. There was however a 20-
fold reduction in the specific activity of Y39A and a 2-3 fold reduction in specific 
activity of M308A compared to the Wild Type.  
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       MWa      WTb      Q37A      Y39F      Y39A     Q104A     M308A   Q314Ac    MW 
      1          2        3          4         5          6           7          8          9 
 
 
a: Molecular Weight marker (10 to 250 kD) 
b: Wild Type glycerol kinase – purified by Pamela Miller 
c: Q314A variant – purified by Damien Terry 
 
Figure 1: SDS-PAGE of purified variant glycerol kinase proteins. For each well, 5 µg of 
protein was loaded. This gel picture is a composite of two separate gels. Wells 1 to 4, 6, 
7 and 9 are from one gel while wells 5 and 8 are from a different gel. 
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IIA
Glc
 Inhibition of Wild Type and Glycerol Kinase Variants 
Figures 2-7 show the IIAGlc inhibition of the Wild Type and alanine variant 
enzymes. The figure on page 35 shows the IIAGlc inhibition of the phenylalanine variant. 
Each of the alanine variants was inhibited by IIAGlc except for the Y39A variant, for 
which no inhibition was detected. The parameters K0.5 for IIA
Glc inhibition were 
determined from fitting the dependence of the specific activity of the Wild Type and 
variant glycerol kinases on IIAGlc concentration to equation 1 while W was determined 
from equation 2. The kinetic constants determined from the IIAGlc inhibition studies 
displayed in Table 3 are the average values of the kinetic constants determined from at 
least two independent experiments.  
The K0.5 for IIA
Glc binding to Wild Type glycerol kinase was found to be 4.6 µM. 
This value compares to what has been previously determined (29). Considering the 
domain I variants, there was a slight increase in the K0.5 value for the domain I Q37 
alanine variant. For the domain I variant Y39A, the K0.5 value was not determined 
because no inhibition was observed.  
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To assess the relative role of the tyrosine hydroxyl group and the aromatic ring in 
the loss of IIAGlc inhibition of the Y39A variant, the Y39F variant was constructed. The 
dependence of its catalytic activity on IIAGlc concentration shows it is inhibited by 
IIAGlc. The IIAGlc inhibition parameters for the Y39F variant are shown in Table 3. The 
K0.5 and W were not significantly different from the values obtained for Wild Type 
EcGK. Considering the domain II variants, the K0.5 was not significantly different from 
the Wild Type.  
The coupling parameter for Wild Type glycerol kinase has been found to be 
approximately 0.08. All of the alanine variants in both domain I and II with the 
exception of Y39A showed increases in the value of the coupling parameter. However, 
the increase is significant only for the Q104A variant, as indicated by the uncertainties in 
the parameter values. W for Y39A variant is equal to 1 since the enzyme was not 
inhibited even at high concentrations of IIAGlc.  
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Figure 2: Wild Type IIAGlc inhibition. The curve shows the fit of equation 1 to one of the 
independent experiments. Each data point is the specific activity determined from the 
indicated concentrations of IIAGlc. The averaged values of the parameters from the fits of 
the individual experiments are shown in Table 2. Assay conditions: 2.5 mM ATP, 0.5 
µg/mL enzyme. 
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Figure 3: Q37A IIAGlc inhibition. The curve shows the fit of equation 1 to one of the 
independent experiments. Each data point is the specific activity determined from the 
indicated concentrations of IIAGlc. The averaged values of the parameters from the fits of 
the individual experiments are shown in Table 2. Assay conditions: 2.5 mM ATP, 0.5 
µg/mL enzyme. 
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Figure 4: Y39A IIAGlc inhibition. The curve shows the fit of equation 1 to one of the 
independent experiments. Each data point is the specific activity determined from the 
indicated concentrations of IIAGlc. The averaged values of the parameters from the fits of 
the individual experiments are shown in Table 2. Assay conditions: 2.5 mM ATP, 5 
µg/mL enzyme. 
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Figure 5: Q104A IIAGlc inhibition. The curve shows the fit of equation 1 to one of the 
independent experiments. Each data point is the specific activity determined from the 
indicated concentrations of IIAGlc. The averaged values of the parameters from the fits of 
the individual experiments are shown in Table 2. Assay conditions: 2.5 mM ATP, 0.1 
µg/mL enzyme. 
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Figure 6: M308A IIAGlc inhibition. The curve shows the fit of equation 1 to one of the 
independent experiments. Each data point is the specific activity determined from the 
indicated concentrations of IIAGlc. The averaged values of the parameters from the fits of 
the individual experiments are shown in Table 2. Assay conditions: 2.5 mM ATP, 5 
µg/mL enzyme. 
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Figure 7: Q314A IIAGlc inhibition. The curve shows the fit of equation 1 to one of the 
independent experiments. Each data point is the specific activity determined from the 
indicated concentrations of IIAGlc. The averaged values of the parameters from the fits of 
the individual experiments are shown in Table 2. Assay conditions: 2.5 mM ATP, 0.5 
µg/mL enzyme. 
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Figure 8: Y39F IIAGlc inhibition. The curve shows the fit of equation 1 to one of the 
independent experiments. Each data point is the specific activity determined from the 
indicated concentrations of IIAGlc. The averaged values of the parameters from the fits of 
the individual experiments are shown in Table 2. Assay conditions: 2.5 mM ATP, 0.5 
µg/mL enzyme. 
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Table 3: IIAGlc inhibition parameters for Wild Type and variant E. coli glycerol kinases 
 
 K0.5, µM W 
Wild Type 4.6 ± 2.3 (2) 0.08 ± 0.07 (2) 
Q37A 9.7 ± 2 (2) 0.13 ± 0.06 (2) 
Y39Aa ND 1 (4) 
Y39F 8.9 ± 1.4 (3) 0.05 ± 0.03 (3) 
Q104A 6.8 ± 2.2 (5) 0.22 ± 0.05 (5) 
M308A 5.2 ± 0.40 (3) 0.13 ± 0.05 (3) 
Q314Aa 6.2 ± 1.6 (3) 0.12 ± 0.03 (3) 
a: These determinations were performed in part by Damien Terry. 
 
Nonlinear least-squares fitting of inhibition data to equation 1 was performed using the computer program 
Kaleidagraph by Synergy Software to obtain the inhibition parameters K0.5. W was determined from 
equation 2. Numbers in parenthesis indicate the number of independent determinations. The uncertainties 
shown for the inhibition parameters were determined from the propagated values of the standard errors of 
parameters obtained where n =2 and from the sample standard deviation where n>2.  
 
ND: Not determined. The K0.5 could not be determined because the Y39A enzyme was not found to be 
inhibited by IIAGlc. 
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IIA
Glc
 Binding Studies to the Variant Y39A 
The apparent loss of IIAGlc inhibition for the Y39A variant raised the question of 
whether the alanine substitution of Y39 abolished binding or the allosteric coupling to 
the catalytic site. To address this question of IIAGlc binding to the Y39A variant, a 
sedimentation velocity method was employed that was previously used to show that the 
IIAGlc binding site amino acids are not sufficient for transplanting allosteric control into 
glycerol kinase of another bacterium, Haemophilus influenzae (37). This method 
determines the increase of the sedimentation coefficient for glycerol kinase upon binding 
to IIAGlc. It benefits from the very low absorbance of IIAGlc at 280 nm due to its lack of 
tyrosine and tryptophan residues. The sedimentation coefficients were determined as 
described under Materials and Methods; preliminary results are shown in Table 4. The 
apparent dissociation constant for the IIAGlc binding to the Y39A variant was determined 
from the IIAGlc concentration dependence of the sedimentation coefficient and results of 
those experiments are shown in the figure on page 41. Three different glycerol kinase 
enzymes were used for those studies: the Wild Type enzyme, the Y39A variant, and an 
E478C DVN variant. The E478C DVN variant does not bind to IIAGlc because of a steric 
clash with the aspartate residue at residue 427 (D of DVN). This enzyme serves to 
measure the effect of solution viscosity increases due to increasing IIAGlc concentrations. 
The results show a small linear decrease in the sedimentation coefficient for the E478C 
DVN variant as IIAGlc concentration was increased. This expected small effect was used 
to correct the apparent sedimentation coefficients for the other two enzymes.  
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The line through the data points shows the fit to equation 6 to estimate the 
dissociation constant for IIAGlc binding to EcGK.  The sedimentation coefficient of the 
Wild Type enzyme showed an apparently hyperbolic dependence upon increasing IIAGlc 
concentration as expected for binding of 4 moles of an 18.1 kDa protein to 1 mole of a 
224 kDa protein. In the absence of IIAGlc, the sedimentation coefficient was about 11.1 
S, which agrees well with a value of 11.5 S calculated from the tetramer structure using 
the program HYDROPRO (38). The data are well described by the fitted line, indicating 
they are consistent with hyperbolic binding of IIAGlc to EcGK. The apparent dissociation 
constant for the binding was found to be 17 ± 7 µM. This value agrees well with the 
value of 7 ± 3 µM that is estimated from linked-functions analysis of IIAGlc inhibition 
(39). 
The sedimentation coefficient for the Y39A variant in the absence of IIAGlc was 
about 10.3, about 1 S less than for Wild Type, indicating that the dimer-tetramer 
equilibrium is shifted toward the dimer by the substitution. This shift is consistent with 
reduced apparent affinity for FBP that is described (Table 4).  
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The sedimentation coefficient for the Y39A variant shows an apparently 
hyperbolic dependence on IIAGlc concentration, as was seen for the Wild Type enzyme. 
The data are well described by the fit to equation 5, shown by the line in Figure 9. This 
result suggests that IIAGlc binding does not affect the dimer-tetramer equilibrium.  
The 1 S increase of the sedimentation coefficient for Y39A on addition of IIAGlc 
was similar to Wild Type, indicating that the Y39A variant binds to IIAGlc.   
The apparent dissociation constant for IIAGlc binding to the Y39A variant was found to 
be 20 ± 6 µM, which agrees well with the dissociation constant obtained for IIAGlc 
binding to the Wild Type enzyme. This result indicates that the Y39A substitution does 
not alter the affinity for IIAGlc binding, but completely uncouples the binding from 
inhibition of catalysis.  
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Table 4: Sedimentation coefficient parameters for EcGK and Y39A GK variant 
 
 Wild Type EcGK Y39A EcGK 
S20,w (-IIA
Glc) 11.2 10.3 
S20,w (+IIA
Glc) 12.3 11.1 
 
S20,w – Sedimentation coefficient corrected to 20
oC. Concentration of IIAGlc used was 90µM.  
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Figure 9: Sedimentation velocity analysis of IIAGlc binding. The lines show the fit of the 
data for EcGK, Y39A and E478C DVN to equation 6 to give the dissociation constants 
shown in the figure. The points show the experimentally-determined sedimentation 
coefficients at the indicated concentration of IIAGlc. The apparent sedimentation 
coefficients for Wild Type and Y39A glycerol kinase were corrected for viscosity 
increases using the E478C DVN mutant as a control which does not bind to IIAGlc. 
Enzyme concentration used was 0.3 mg/ml. 
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FBP Regulation of Wild Type and Glycerol Kinase Variants  
Inhibition by FBP was investigated by assessing the dependence of the activity of 
the glycerol kinases on FBP concentration as shown in Figures 10-16. FBP concentration 
was varied from 0 - 10mM and the inhibition parameters of the glycerol kinase variants 
to FBP determined. The kinetic parameters from the FBP inhibition studies are shown in 
Table 5. The inhibition parameters K0.5 and nH were determined from fitting the data 
from the inhibition curves to equation 3 while W was determined from equation 2.  
For the domain I variants Q37A, Y39A and Y39F, the K0.5 was increased 
compared to Wild Type. The K0.5 of the domain I variant Q104A was not significantly 
affected by the alanine substitution. For the domain II variants, the affinity of the 
M308A variant for FBP was increased due to the substitution, showing a two-fold 
decrease in the K0.5 compared to Wild Type glycerol kinase. The K0.5 of Q314A was 
however not affected.  
Only two of the variant enzymes, Q37 and Q314 showed changes in W. W was 
increased slightly by the alanine substitutions of these residues. For all of the variants, 
FBP inhibition was positively cooperative as for Wild Type glycerol kinase. The Hill 
coefficient was increased for the Q37A and Q104A variants but was similar to Wild 
Type for the rest of the mutants. The phenotypes of the variants on MGSA (Table 6) 
were characteristic of the effects of the substitutions on the K0.5; the significance of 
which are discussed later. 
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Figure 10: Wild Type FBP inhibition. Each data point is the specific activity determined 
from the indicated concentrations of FBP. The curve shows the fit of equation 3 to one 
of the independent experiments. The averaged values of the parameters from the fits of 
the individual experiments are shown in Table 4. Assay conditions: 2.5 mM ATP, 0.5 
µg/mL enzyme.  
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Figure 11: Q37A FBP inhibition. Each data point is the specific activity determined from 
the indicated concentrations of FBP. The curve shows the fit of equation 3 to one of the 
independent experiments. The averaged values of the parameters from the fits of the 
individual experiments are shown in Table 4. Assay conditions: 2.5 mM ATP, 0.5 
µg/mL enzyme.  
  
 
 
 
 45
0
0.5
1
1.5
2
2.5
0.001 0.01 0.1 1 10 100
Y39A FBP Inhibition
[FBP], mM
 
Figure 12: Y39A FBP inhibition. Each data point is the specific activity determined from 
the indicated concentrations of FBP. The curve shows the fit of equation 3 to one of the 
independent experiments. The averaged values of the parameters from the fits of the 
individual experiments are shown in Table 4. Assay conditions: 2.5 mM ATP, 5 µg/mL 
enzyme.  
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Figure 13: Y39F FBP inhibition. Each data point is the specific activity determined from 
the indicated concentrations of FBP. The curve shows the fit of equation 3 to one of the 
independent experiments. The averaged values of the parameters from the fits of the 
individual experiments are shown in Table 4. Assay conditions: 2.5 mM ATP, 0.5 
µg/mL enzyme.  
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Figure 14: Q104A FBP inhibition. Each data point is the specific activity determined 
from the indicated concentrations of FBP. The curve shows the fit of equation 3 to one 
of the independent experiments. The averaged values of the parameters from the fits of 
the individual experiments are shown in Table 4. Assay conditions: 2.5 mM ATP, 1 
µg/mL enzyme.  
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Figure 15: M308A FBP inhibition. Each data point is the specific activity determined 
from the indicated concentrations of FBP. The curve shows the fit of equation 3 to one 
of the independent experiments. The averaged values of the parameters from the fits of 
the individual experiments are shown in Table 4. Assay conditions: 2.5 mM ATP, 5 
µg/mL enzyme.  
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Figure 16: Q314A FBP inhibition. Each data point is the specific activity determined 
from the indicated concentrations of FBP. The curve shows the fit of equation 3 to one 
of the independent experiments. The averaged values of the parameters from the fits of 
the individual experiments are shown in Table 4. Assay conditions: 2.5 mM ATP, 0.5 
µg/mL enzyme.  
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Table 5: FBP inhibition parameters for Wild Type and variant E. coli glycerol kinase 
 
 K0.5, µM W nH 
Wild Typea 264 ± 134 (3) 0.04 ± 0.02 (3) 1.2 ± 0.3 (3) 
Q37A 1284 ± 247 (3) 0.15 ± 0.09 (3) 1.9 ± 0.8 (3) 
Y39A 1722 ± 204 (2) 0.06 ± 0.06 (2) 1.4 ± 0.2 (2) 
Y39F 965 ± 74 (3) 0.04 ± 0.01 (3) 2.0 ± 0.1 (3) 
Q104A 425 ± 9 (3) 0.02 ± 0.01 (3) 1.7 ± 0.1 (3) 
M308A 97 ± 19 (2) 0.04 ± 0.02 (2) 1.5 ± 0.2 (2) 
Q314Aa 317 ± 30 (2) 0.11 ± 0.04 (2) 1.6 ± 0.3 (2) 
a: These determinations were performed in part by Damien Terry 
 
Nonlinear least-squares fitting of inhibition data to equation 3 was performed using the computer program 
Kaleidagraph by Synergy Software to obtain the inhibition parameters K0.5 and nH. W was determined 
from equation 2. Numbers in parenthesis indicate the number of independent determinations. The 
uncertainties shown for the inhibition parameters were determined from the propagated values of the 
standard errors of parameters obtained where n=2 and from the sample standard deviation where n>2.  
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Table 6: Phenotypes of cells transformed with variant glycerol kinase  
 
E. coli Glycerol Kinase Phenotype of Colonies on MGSA plates 
Wild Type Purple 
Q37A Purple with foggy halo 
Y39A Purple with foggy halo 
Y39F Purple with slightly foggy halo 
Q104A Purple with slightly foggy halo 
M308A Pink  
Q314A Purple 
 
The phenotypes of the variant E. coli were recorded after overnight growth on MGSA plates.  
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Effects of the Domain Bridging Amino Acid Substitutions on Enzyme Catalytic 
Properties  
Initial velocity kinetic studies for each of the variant glycerol kinases were 
performed in the forward direction using the ADP coupled spectrophotometric assay at 
pH 7.0 and 25°C with a Beckman DU800 spectrophotometer. In each of the assays, 
glycerol was added to the enzyme to a final concentration of 10 mM. The dependence of 
the initial velocity of Wild Type and each glycerol kinase variant on the concentration of 
the substrate ATP is shown in Figures 17-23. The kinetic data obtained from the assays 
were fit to equation 4 in Materials and Methods. The kinetic constants were obtained 
from the fits of at least two independent experiments and are shown in Table 7.  
Considering domain I, the alanine substitutions had the effect of reducing the 
Vmax in Q37A and Y39A. The reduction in Vmax was most pronounced and significant in 
Y39A. Compared to the Vmax of the Wild Type enzyme, Q37A was reduced two-fold, 
while Y39A was reduced four-fold. The Vmax of Y39F was however unaffected by the 
substitutions, while it was increased for the Q140A variant. For domain II, the Vmax of 
M308A was significantly affected, with a three-fold reduction while the Vmax of Q314A 
was slightly increased by the substitution.  
The Michaelis constant (Km) for ATP of Wild Type glycerol kinase was also 
compared to the variant enzymes. The Km of the domain I variants Q37A and Y39F were 
not significantly affected. The alanine substitutions in Y39 and Q104 however resulted 
in an increased Km. The Km of Y39A was increased about twelve-fold higher than that of 
Wild Type glycerol kinase while Q104A had an approximately seven-fold increase in 
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the Km. In the determination of the Km for Y39A and Q104A, the apparent binding 
affinity for ATP of these variants appeared to shift the Km to the right. The ATP 
concentrations were therefore varied up to 2.5 mM. Considering domain II, the Km was 
not affected by the alanine substitution of both M308 and Q314.  
Due to the observed large effects of the Y39A substitution on the enzyme 
catalytic properties as had been observed for IIAGlc inhibition, the second substrate 
glycerol was varied to obtain the Michaelis constant for glycerol and the dissociation 
constant for ATP. The results are shown in Table 8. The Vmax and Km for ATP for the 
Y39A variant determined from both substrates agreed well with the value obtained from 
varying ATP alone. There was a significant increase in the Km for ATP and a decrease in 
the Vmax. The results showed that the Km for glycerol was also increased about 21-fold 
higher for Y39A compared to Wild Type. The dissociation constants (Kia) determined 
showed that the alanine substitution of Y39 resulted in a decrease in the Kia for ATP.  
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Figure 17: Wild Type ATP kinetics. Each data point is the specific activity determined 
from the indicated concentrations of ATP. The curve shows the fit to equation 4 to one 
of the independent experiments. The parameters from the average fit are shown in Table 
5. The enzyme concentration used in each assay was 0.5 µg/mL. 
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Figure 18: Q37A ATP kinetics. Each data point is the specific activity determined from 
the indicated concentrations of ATP. The curve shows the fit to equation 4 to one of the 
independent experiments. The averaged values of the parameters from the fits of the 
individual experiments are shown in Table 5. The enzyme concentration used in each 
assay was 0.5 µg/mL. 
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Figure 19: Y39A ATP kinetics. Each data point is the specific activity determined from 
the indicated concentrations of ATP. The curve shows the fit to equation 4 to one of the 
independent experiments. The averaged values of the parameters from the fits of the 
individual experiments are shown in Table 5. The enzyme concentration used in each 
assay was 5 µg/mL. 
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Figure 20: Y39F ATP kinetics. Each data point is the specific activity determined from 
the indicated concentrations of ATP. The curve shows the fit to equation 4 to one of the 
independent experiments. The parameters from the average fit are shown in Table 5. The 
enzyme concentration used in each assay was 0.5 µg/mL. 
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Figure 21: Q104A ATP kinetics. Each data point is the specific activity determined from 
the indicated concentrations of ATP. The curve shows the fit to equation 4 to one of the 
independent experiments. The parameters from the average fit are shown in Table 5. The 
enzyme concentration used in each assay was 1 µg/mL. 
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Figure 22: M308A ATP kinetics. Each data point is the specific activity determined from 
the indicated concentrations of ATP. The curve shows the fit to equation 4 to one of the 
independent experiments. The parameters from the average fit are shown in Table 5. The 
enzyme concentration used in each assay was 5 µg/mL. 
. 
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Figure 23: Q314A ATP kinetics. Each data point is the specific activity determined from 
the indicated concentrations of ATP. The curve shows the fit to equation 4 to one of the 
independent experiments. The parameters from the average fit are shown in Table 5. The 
enzyme concentration used in each assay was 0.5 µg/mL. 
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Table 7: Steady state kinetics for Wild Type and variant E. coli glycerol kinase 
 
 Vmax, U/mg Km
ATP, µM 
Wild Typea 12.9 ± 4.6 (2) 11.1 ± 13 (2) 
Q37A 8.6 ± 0.7 (2) 15.8 ± 4 (2) 
Y39A 3.4 ± 0.2 (2) 136 ± 29 (2) 
Y39F 21.4 ± 2.7 (3) 11.7 ± 2.7 (3) 
Q104A 22.5 ± 4.3 (3) 78 ± 25 (3) 
M308Aa 6.6 ± 0.3 (1) 12.6 ± 3.4 (3) 
Q314Aa 20.9 ± 0.9 (1) 14.8 ± 2.8 (3)  
a: These determinations were performed in part by Damien Terry 
 
Nonlinear least-squares fitting of inhibition data to equation 4 was performed using the computer program 
Kaleidagraph by Synergy Software to obtain the inhibition parameters Vmax and Km
ATP. Numbers in 
parenthesis indicate the number of independent determinations. The uncertainties shown for the inhibition 
parameters were determined from the propagated values of the standard errors of parameters obtained 
where n=2 and from the sample standard deviation where n>2. Where n=1, the enzyme was not found to 
be stable in the crystalline ammonium sulfate form it was stored in, resulting in an irreversible loss of 
activity which prevented the accurate determination of the Vmax over time.  The reported vaules are 
therefore for the earliest determination. The uncertainties shown for the single determinations are the 
standard errors of the parameters.  
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Table 8: Michaelis and dissociation constants of Wild Type and Y39A glycerol kinase 
 
 Vmax, U/mg Km for ATP, µM Kia for ATP, µM Km for glycerol, µM 
Wild 
Type 
15.7 ± 0.3 a 11.7 ± 0.7 86 ± 25a 4.9 ± 1.2 a 
Y39Ab 5.1 ± 0.1 110 ± 8 43 ± 15 105 ± 7 
a: Results from Pettigrew et al., (12). 
b: These determinations were performed by Shanna Mayorov. 
 
Nonlinear least-squares fitting of inhibition data to equation 5 was performed using the computer program 
EnzFitter (Biosoft, Cambridge, U.K) to obtain the inhibition parameters Vmax, Km for ATP, Kia for ATP, 
and Km for glycerol. The uncertainties shown for the inhibition parameters are the standard errors for the 
parameters.                                               
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CHAPTER IV 
DISCUSSION 
  
Five amino acids were identified to be within 7 Å of an Arg369 residue which was 
found to be important in IIAGlc inhibition. Three of the amino acids (Q37, Y39 and 
Q104) bridge domain I and Arg369 of EcGK while the other two bridge domain II and 
Arg369 of EcGK. This work used structure perturbation studies to understand the role of 
these domain bridging interactions in the regulation of EcGK by the allosteric inhibitor 
IIAGlc. The effects of the substitutions on FBP inhibition and catalytic properties of the 
enzyme were also assessed. 
 
Importance of the Domain Bridging Amino Acids in IIA
Glc
 Regulation of EcGK  
 
The effects of the substitutions of the domain bridging amino acids on the 
regulation of the EcGK by the inhibitors IIAGlc are discussed. IIAGlc inhibition for the 
domain I mutants were interesting since Y39A exhibited no IIAGlc inhibition, while 
Q37A and Q104A had reduced affinity for IIAGlc. The inhibition parameter, K0.5, is the 
apparent dissociation constant for allosteric effector binding and gives an indication of 
the binding affinity of the allosteric effector to the enzyme. The increased K0.5 values of 
the domain I alanine variants of Q37 and Q104 therefore suggest that the interactions of 
the domain I residues are important for regulating binding of the inhibitor IIAGlc to the 
EcGK enzyme. The interaction of Y39 with Arg369 seems particularly important in 
coupling binding with IIAGlc inhibition. This is because the Y39A substitution had the 
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effect of causing a lack of inhibition of the EcGK enzyme. The sedimentation velocity 
experiments however showed that the IIAGlc was still binding to the Y39A variant. The 
alanine substitution of this residue therefore appeared to uncouple binding of IIAGlc and 
inhibition. The coupling factor, W, was increased for the domain I residues Q37, Y39 
and Q104. The increase was however only significant for the Y39A variant. The value of 
W for Y39A was determined to be equal because even at high concentrations of IIAGlc 
the enzyme was not found to be inhibited. The increase in the coupling factor, W, 
reiterates the importance of the domain I residue Y39 in IIAGlc inhibition. The value of 
W is >1 if the allosteric effector increases the Vmax, and is <1 if Vmax is reduced by the 
allosteric effector. The alanine substitutions of the Y39 residue therefore appeared to 
decrease the ability of the EcGK enzyme to reduce the Vmax.  
To evaluate the role of the tyrosine hydroxyl group and aromatic ring in the loss 
of IIAGlc inhibition of the Y39A variant, the Y39F variant was constructed. The increase 
in K0.5 for the Y39F variant suggests that the hydroxyl group interaction of Y39 with 
Arg369 may still be important in IIAGlc binding. The large effect of the Y39A substitution 
on IIAGlc inhibition was therefore largely due to the loss of the interactions of the 
aromatic ring. The hydroxyl group interaction of Y39 with Arg369 however does not 
appear to be very important for inhibition since W for the Y39F variant was not 
significantly different from the Wild Type enzyme. 
The W for the domain II bridging variants was not significantly different from 
Wild Type, suggesting that the alanine mutations at these sites did not affect the ability 
of the enzyme to reduce the Vmax during IIA
Glc inhibition. The K0.5 for IIA
Glc binding 
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also remained similar to Wild Type, indicating that the domain II alanine substitutions 
did not affect the affinity for the inhibitor. These results indicate that the domain II 
bridging interactions with Arg369 may not be important in regulating inhibition of the 
enzyme by IIAGlc. 
Since the analysis of the crystal structure of the EcGK by Hurley et al. (5) 
showed Arg369 as an acid residue likely to be important in the IIAGlc regulation of EcGK, 
the crystal structures of two variant EcGK were superimposed in an attempt to illuminate 
any differences which may exist between the inhibited and uninhibited forms of the 
enzyme around the Arg369 residue. A previously determined crystal structure of EcGK 
with FBP bound was used to mimic the inhibited closed conformation of EcGK (40) and 
superposed with the structure of an EcGK variant S58W variant which is not inhibited 
by FBP (41). The crystal structure of the S58W variant of EcGK shows two asymmetric 
monomers in the dimer and the open form was used to mimic the uninhibited 
conformation of EcGK. The superimposed crystal structures shown in Figure 24 showed 
some differences in movement for the domain I amino acid residues within 4 Å which 
interact with the Arg369 loop. The domain II amino acid residues within 4 Å interacting 
with the Arg369 loop however do not seem affected by the open or closed conformations 
(Pettigrew, D.W unpublished). The observed movement of the domain I residues in close 
proximity to Arg369 is in agreement with the observed effects of domain I in regulating 
IIAGlc binding to the enzyme. 
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Solid color: EcGK·FBP complex (PDB: 1BO5). Inhibited closed conformation  
CPK color: S58W·gol·ADPCF2P complex (PDB: 1BWF). Open uninhibited conformation (asymmetric 
monomers in dimer) 
 
Figure 24: Superimposed crystal structures of E. coli glycerol kinase. The superimposed 
structure is a composite of structures from pdb files 1BO5 (40) and 1BWF (41). The 
pictures were generated from the crystal structures of EcGK using PyMOL (generously 
performed by Dr. Pingwei Li of Texas A&M University) and the superposition done 
using Deep View/Swiss-PdbViewer version 3.7 (42) and POV-Ray version 3.1 
(www.povray.org) by Dr. Donald Pettigrew of Texas A&M University. 
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Importance of the Domain Bridging Amino Acids in FBP Regulation of EcGK  
Previous studies have suggested that FBP and IIAGlc inhibition can be genetically 
separated. The effects of the R369A substitution which formed the basis of this study 
also indicated that the Arg369 residue was important only in IIAGlc inhibition, but had no 
observable effects on FBP inhibition. Inhibition to EcGK by FBP for the domain 
bridging variants was therefore investigated to evaluate the importance of the domain 
bridging amino acids in FBP inhibition.  
From Table 5, it can be seen that with the exception of Q104A, the domain I 
alanine substitutions resulted in significant increases in the K0.5 for FBP binding. The 
apparent binding affinity for FBP therefore appeared to be reduced due to the alanine 
substitutions. The domain I residues Q37 and Y39 therefore appear important in 
regulating FBP binding to the enzyme. For Y39, the FBP parameters of the 
phenylalanine variant were used to assess the importance of the hydroxyl group 
interaction with R369 in FBP inhibition. From the results in Table 5 for the Y39F 
variant, the hydroxyl group interaction of Y39 with Arg369 appears important in FBP 
binding although to a lesser extent than the hydrophobic portion. This is because 
removal of the hydroxyl group interaction by the phenylalanine substitution still affected 
the affinity of the enzyme for FBP as seen by the increase in the K0.5. The K0.5 for FBP 
binding of the domain I variant Q104A was not affected by the alanine substitutions, 
suggesting that this residue does not play a significant role in FBP binding. The coupling 
parameter, W, was not affected by any of the amino acid substitutions of the domain         
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I bridging residues. The residues studied may therefore not be essential in regulating the 
Vmax during FBP inhibition. 
The domain II variant, M308A was interesting because the K0.5 for FBP binding 
was lower than that of Wild Type. This observation suggests that the alanine substitution 
resulted in a variant which had a higher affinity for FBP. The implication of this for FBP 
binding is unclear. It is possible that the M308 residue is in the allosteric network for the 
regulation of FBP binding, and the interaction of M308 with Arg369 acts as a check to 
control the affinity of FBP binding. For the domain II substitutions, the K0.5 for FBP 
binding of the Q314A was not affected by the alanine substitution. The Q314 interaction 
with Arg369 may therefore be unimportant in regulating FBP binding. The W for domain 
II variants, M308A and Q314A were not significantly different from that of Wild Type, 
suggesting that these residues may unimportant for inhibition of the enzyme by FBP. 
The Hill coefficient for all the domain bridging variants studied were greater than one, 
indicating that the amino acid substitutions did not affect the positive cooperativity of 
FBP binding to EcGK.  
The observation that some domain I residues important for IIAGlc inhibition were 
also important for FBP inhibition was interesting. This observation suggests that signals 
involved in IIAGlc inhibition may go through channels which overlap the paths involved 
in FBP inhibition. Novotny et al, (18) and subsequently Saier (19) concluded that the 
regulation of FBP and IIAGlc inhibition operates by independent mechanisms because: 1) 
Mutants have been isolated which lack one type of regulation but completely retain 
regulation by the other. 2) IIAGlc inhibition of EcGK has not been found to be 
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concentration dependent but FBP inhibition of EcGK has been found to be concentration 
dependent. 3) The inhibitory effects of FBP and IIAGlc have been found to be additive at 
subsaturating conditions. These results however suggest that the domain I bridging 
residues Q37 and Y39 may be important for both FBP and IIAGlc inhibition. 
The phenotypes of the variants on MGSA plates (displayed in Table 6) are also 
consistent with the kinetic results. Wild Type glycerol kinase is purple on MGSA. Cells 
which lose FBP control of glycerol kinase have been observed to have a foggy purple 
phenotype on MacConkey glycerol, due to the uncontrolled use of glycerol as a carbon 
source. The domain I variants had a foggy purple phenotype consistent with the higher 
K0.5 values which are indicative of loss of FBP control. The M308A variant also had a 
pink phenotype consistent with the lower K0.5 value which is indicative of more FBP 
control. The Q314A variant which had K0.5 value similar to Wild Type was still purple.   
 
Effects of the Domain Bridging Substitutions on the Catalytic Properties of EcGK 
The Arg369 residue which penetrates from one subunit into another is found 
approximately 10 Å from the catalytic cleft of EcGK. The kinetic parameters Vmax and 
Km were therefore obtained for one of the substrates, ATP to assess the effects of the 
Arg369 domain bridging substitutions on the catalytic properties.  
The alanine substitutions of the domain I residues Q37A, Y39A and Q104A 
affected the catalytic properties. The effect was however mild in Q37A, where the Vmax 
was reduced by about 30% and the Michaelis constant was unaffected. This residue 
therefore appears to be important for catalysis, but not for substrate binding. The Q37A 
 70
substitution may have resulted in a local change in the enzyme which was not favorable 
for one of the chemical steps in the enzyme catalyzed reaction resulting in the observed 
reduction in the Vmax. The major effect on the catalytic properties was observed for the 
domain I Y39A substitution. The Vmax was substantially reduced by about 80% and the 
Michaelis constant increased about 12-fold. The large effects of this mutation on the 
catalytic properties were interesting because this residue appeared to be vital for IIAGlc 
inhibition. The observed decrease in the Vmax is suggestive that the interactions and/or 
local motions of the Y39 residue with Arg369 may be important in regulating the activity 
of the enzyme.  The increase in the Michaelis constant also suggests that the Y39 residue 
is important in ATP binding.  
Due to the large catalytic effects observed for the Y39A mutation, the second 
substrate, glycerol, was also varied in the assays to allow determination of the Michaelis 
constant for glycerol and the dissociation constant for ATP.  The Michaelis constant and 
dissociation constants are displayed in Table 8. The results show that the Y39A mutation 
resulted in an increase in the Michaelis constant for both ATP and glycerol. In EcGK, it 
has been observed that the Michaelis constants for the substrates ATP and glycerol are 
about 5 to 10 fold smaller than the substrate dissociation constants. This observation 
suggests that a step after the formation of the ternary complexes may be rate limiting. 
The Y39A substitution however did not eliminate the difference between the Michaelis 
and dissociation constants for ATP. Unlike the Wild Type enzyme however, the 
Michaelis constant was about 2-fold larger than the dissociation constant for ATP. The 
Y39A substitution may therefore have resulted in a switch of the rate limiting step to 
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occur before the formation of the ternary complexes. The effects of the Y39A 
substitution on the catalytic properties of EcGK are somewhat similar. The Vmax of the 
R369A variant was decreased similar to what was observed for Y39A. There was also a 
significant increase in the Km for ATP and glycerol for both variants. The alanine of both 
residues also affected the Km/Kia ratio for ATP binding. These results therefore suggest 
that the interaction of Arg369 and Y39 may be important for regulating the formation of 
the ternary complexes during catalysis of EGK. 
The phenylalanine variant of Y39 constructed to assess the hydrogen bonding 
interactions of the hydroxyl group on the tyrosine residue with Arg369 showed some 
interesting results. The Y39F substitution had very little effects on the catalytic 
properties of EcGK. There appeared to be no significant effect on the Michaelis 
constant, while the Vmax was slightly increased approximately two-fold. The observed 
two-fold increase in the Vmax, although small, may indicate an associated increase in the 
rate of motion of the interaction between Y39F and Arg369. The hydroxyl group of Y39 
may therefore be important in regulating the rate of motion in its interaction with the 
Arg369 residue but may not be vital during catalysis. The interactions of the hydrophobic 
portion of the tyrosine residue with Arg369 may therefore be more important in the 
enzyme catalysis since the alanine substitution reduced the area of the hydrophobic 
group interacting with Arg369, with a resultant reduction in the Vmax and an increase in 
the Michaelis constant.  
For the third domain I variant, Q104A, the Vmax appeared to increase almost two-
fold, while the Michaelis constant increased about eight-fold compared to the Wild Type 
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enzyme. The Q104A substitution therefore appeared to result in a decrease of the 
binding affinity for ATP, but increased the catalytic rate. The interaction of this residue 
with the Arg369 residue may therefore be important for substrate binding, but not 
significantly important for catalysis. The increase in Vmax observed may be due to a 
conformational change resulting from the alanine substitution of Q104 which was 
favorable for an increased the rate of catalysis of the enzyme.  
With the domain II alanine substitutions, M308A and Q314A, only the M308A 
substitution affected the catalytic properties of the enzyme. The Vmax and Michaelis 
constant of the Q314A variant were unaffected by the alanine substitution, suggesting 
that the interaction of this residue with Arg369 is not important in catalysis or substrate 
binding.  The Vmax of the M308A variant was however approximately 60% lower than 
that of Wild Type, but the Michaelis constant remained unaffected. This interaction of 
the M308A residue with Arg369 therefore appears important during catalysis of the 
enzyme. The different values of Vmax seen for the EcGK variants may be related to 
different contributions of each residue interaction with Arg369 and the effect on the rate 
of the active site closure motion. For example, the Y39F substitution resulted in an 
increase in the Vmax; apparently indicating an associated increase in the rate of motion at 
the active site.  
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The kinetic results indicate that the hydrogen bonding interactions of the domain 
I residues, Q37A and Y39A with the guanidino group of Arg369, as well as that of the 
domain II residue M308A with Arg369 are important during catalysis. The interactions of 
the domain I residues however appear to be more important for substrate binding than 
the interactions of the domain II residues with Arg369. Since these residues are far 
removed from the catalytic site of the enzyme, the results indicate that the domain I may 
form part of the network in communicating ATP binding to the active site during 
catalysis. 
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CHAPTER V 
CONCLUSIONS 
 
The results from this study indicate that the domain I bridging interactions with 
Arg369 are important in IIAGlc regulation of the E. coli glycerol kinase enzyme. The 
domain II bridging interactions appear to be unimportant in regulating IIAGlc inhibition. 
The domain I bridging residues Q37 and Y39 were also found to be important in FBP 
inhibition. From the observations of Novotny et al., (18), EcGK has the ability to 
genetically separate FBP and IIAGlc inhibition. These results however indicate that some 
residues seen to be involved in IIAGlc regulation also appear to be involved in FBP 
regulation. In catalysis, with the exception of Q314, the other domain bridging residues 
appear to be important for substrate binding and/or catalysis.  
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